In conclusion, global iPLA2β deficiency in DEN-treated mice limited HCC development with mechanisms involving the induction of cell-cycle arrest and attenuation of inflammatory markers Bcl2, IL-1β, IL-10, and VCAM-1. The gene discussed is BCL2; the disease is hepatocellular carcinoma.